Hepatic cytochrome P450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 12, 2012, Pages 1793-1801

  Yokotani, Kaori ^a,b   Chiba, Tsuyoshi ^a   Sato, Yoko ^a   Taki, Yuko ^c   Yamada, Shizuo ^c   Shinozuka, Kazumasa ^d   Murata, Masatsune ^b   Umegaki, Keizo ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b OCHANOMIZU UNIVERSITY   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

^d MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Coleus forskohlii; drug herb interaction; hepatic CYP2C; herbal supplement; warfarin

Indexed keywords

ALBUMIN; COLEUS FORSKOHLII EXTRACT; CYTOCHROME P450; CYTOCHROME P450 2C; FORSKOLIN; OXYGENASE; PLANT EXTRACT; UNCLASSIFIED DRUG; WARFARIN; WARFARIN 7 HYDROXYLASE;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING PARAMETERS; BODY WEIGHT; COLEUS; COLEUS FORSKOHLII; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER LEVEL; LIVER MICROSOME; LIVER WEIGHT; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN INTAKE; TREATMENT DURATION;

ANIMALS; ANTICOAGULANTS; CASEINS; COLEUS; CYTOCHROME P-450 ENZYME SYSTEM; DIET; DIETARY PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; HERB-DRUG INTERACTIONS; LIVER; MALE; MICE; MICE, INBRED ICR; MICROSOMES, LIVER; PLANT EXTRACTS; WARFARIN;

EID: 84869096085     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01563.x     Document Type: Article

References (37)

1. Gershwin ME, et al,. Public safety and dietary supplementation. Ann N Y Acad Sci 2010; 1190: 104-117.
2. Bent S, Ko R,. Commonly used herbal medicines in the United States: a review. Am J Med 2004; 116: 478-485.
3. van Breemen RB, et al,. Ensuring the safety of botanical dietary supplements. Am J Clin Nutr 2008; 87: 509S-513S.
4. Izzo AA, Ernst E,. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69: 1777-1798.
5. Ulbricht C, et al,. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008; 9: 1063-1120.
6. Sleath B, et al,. Ethnicity and physician-older patient communication about alternative therapies. J Altern Complement Med 2001; 7: 329-335.
7. Giveon SM, et al,. Are people who use 'natural drugs' aware of their potentially harmful side effects and reporting to family physician? Patient Educ Couns 2004; 53: 5-11.
8. Zhou SF, Lai X,. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008; 9: 394-409.
9. Uchida S, et al,. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46: 1290-1298.
10. Pittler MH, et al,. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev 2005; 6: 93-111.
11. Bhat SV, et al,. Structures and stereochemistry of new labdane diterpenoids from Coleus forskohlii briq. Tetrahedron Lett 1977; 19: 1669-1672.
12. Ammon HP, Muller AB,. Forskolin: from an ayurvedic remedy to a modern agent. Planta Med 1985; 51: 473-477.
13. Bauer K, et al,. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther 1993; 53: 76-83.
14. Baumann G, et al,. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy-a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990; 16: 93-100.
15. Allen DO, et al,. Relationships between cyclic AMP levels and lipolysis in fat cells after isoproterenol and forskolin stimulation. J Pharmacol Exp Ther 1986; 238: 659-664.
16. Okuda H, et al,. Relationship between cyclic AMP production and lipolysis induced by forskolin in rat fat cells. J Lipid Res 1992; 33: 225-231.
17. Han LK, et al,. Effects of Coleus forskohlii on fat storage in ovariectomized rats. Yakugaku Zasshi 2005; 125: 449-453.
18. Henderson S, et al,. Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. J Int Soc Sports Nutr 2005; 2: 54-62.
19. Godard MP, et al,. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res 2005; 13: 1335-1343.
20. Virgona N, et al,. Coleus forskohlii extract induces hepatic cytochrome P450 enzymes in mice. Food Chem Toxicol 2011; 50: 750-755.
21. Reagan-Shaw S, et al,. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
22. Holbrook AM, et al,. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-1106.
23. Fugh-Berman A, Ernst E,. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587-595.
24. Palareti G, Legnani C,. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet 1996; 30: 300-313.
25. Taki Y, et al,. Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice. Phytomedicine 2011; 19: 177-182.
26. Kumar V, et al,. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 2006; 34: 1966-1975.
27. Taki Y, et al,. Effects of Ginkgo biloba extract on the pharmacokinetics and pharmacodynamics of tolbutamide in protein-restricted rats. J Pharm Pharmacol 2011; 63: 1238-1243.
28. Reeves PG, et al,. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993; 123: 1939-1951.
29. Sato K, et al,. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. Jpn J Pharmacol 1998; 78: 191-197.
30. Virgona N, et al,. A rapid HPLC with evaporative light scattering method for quantification of forskolin in multi-herbal weight-loss solid oral dosage forms. Pharmazie 2010; 65: 322-326.
31. Umegaki K, et al,. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn J Pharmacol 2002; 90: 345-351.
32. Martignoni M, ed. Species and Strain Differences in Drug Metabolism in Liver and Intestine, University of Groningen, 2006.
33. Ding X, Staudinger JL,. Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J Pharmacol Exp Ther 2005; 312: 849-856.
34. Christenson JT, et al,. The effect of forskolin on blood flow, platelet metabolism, aggregation and ATP release. Vasa 1995; 24: 56-61.
35. Agarwal KC, et al,. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep. Thromb Haemost 1989; 61: 106-110.
36. Tompkins LM, Wallace AD,. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol 2007; 21: 176-181.
37. Rendic S, Di Carlo FJ,. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580.